Drug Trial Radar · NCT03353025
Study on Therapy of Non-invasive Prolactinoma
Last checked: Nov 20, 2026Latest source record: Nov 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
394
Planned (sponsor's estimate)
Start
Jan 1, 2016
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 24, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
Conditions
- Prolactinoma
Interventions
transsphenoidal surgery treatmentProcedure
transsphenoidal surgery treatment
dopamine agonist treatmentDrug
Minimum effective dose of dopamine agonist,bromocriptine,treat prolactinona
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endocrine remission rateTime frame: five-year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen 5010 program
Guangzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.